Literature DB >> 16514311

Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml.

Laura Waters1, S Mandalia, David Asboe.   

Abstract

Traditionally an HIV viral load of over 1000 copies/ml was presumed necessary for genotypic resistance testing. We performed a retrospective analysis to assess rates of viral amplification on viral loads between 50 and 1000 copies/ml. Amplification was significantly more likely for 200-1000 copies/ml than 50-200 copies/ml; most samples amplified successfully, supporting the use of genotyping for low-level viraemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16514311     DOI: 10.1097/01.aids.0000216381.37679.69

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  3 in total

1.  Clinical utility of genotypic resistance tests for HIV-1-infected patients with low-level virological failure.

Authors:  A Elgalib; M Perry; M Aboud; J Mullen; S O'Shea; I L Chrystie; R Kulasegaram; C Y W Tong
Journal:  J Clin Microbiol       Date:  2010-07-14       Impact factor: 5.948

2.  HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL.

Authors:  Yumi Mitsuya; Mark A Winters; W Jeffrey Fessel; Soo-Yon Rhee; Sally Slome; Jason Flamm; Michael Horberg; Leo Hurley; Daniel Klein; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

3.  Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm.

Authors:  Sarah E Rutstein; Mina C Hosseinipour; Morris Weinberger; Stephanie B Wheeler; Andrea K Biddle; Carole L Wallis; Pachamuthu Balakrishnan; John W Mellors; Mariza Morgado; Shanmugam Saravanan; Srikanth Tripathy; Saran Vardhanabhuti; Joseph J Eron; William C Miller
Journal:  BMC Infect Dis       Date:  2016-06-13       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.